Form 4: Lyell Immunopharma CFO Charles W. Newton Acquires 200,000 Shares

Lyell Immunopharma's CFO, Charles W. Newton, purchased 200,000 shares of common stock at an average price of $0.5581 on March 17, 2025.

Summary

• On March 17, 2025, Charles W. Newton, the Chief Financial Officer of Lyell Immunopharma, Inc. (LYEL), acquired 200,000 shares of common stock.
• The shares were purchased at a weighted average price of $0.5581, with individual prices ranging from $0.54 to $0.56.
• Following the transaction, Newton directly owns 172,725 shares and indirectly owns 200,000 shares through The Charles & Lisa Newton Living Trust, of which he is a co-trustee and co-grantor.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying can be a positive signal, but the impact is limited without further context.

Positives

• The CFO's purchase of shares could be interpreted as a positive signal about the company's prospects.

Industry Context

Insider buying is often seen as a positive sign, suggesting that a company insider believes the company's stock is undervalued. However, it's important to consider the size of the purchase relative to the insider's overall holdings and the company's market capitalization.

Stakeholder Impact

• The stock purchase by the CFO could potentially increase investor confidence.

Key Dates